Last Updated: November 16, 2026

Drug Sales Trends for ZOHYDRO ER

« Back to Dashboard


Drug Sales Revenue Trends for ZOHYDRO ER
Drug Units Sold Trends for ZOHYDRO ER

Zohydro ER Market Analysis, Sales History, Patent Position, and Revenue Projections

Last updated: September 5, 2026

Zohydro ER is no longer a meaningful commercial growth product. The hydrocodone bitartrate extended-release capsule was approved by the FDA in 2013, launched by Zogenix in 2014, and later commercialized by Pernix Therapeutics. Its addressable market contracted because of opioid prescribing restrictions, payer controls, abuse liability concerns, competition from other extended-release opioids, and the absence of an abuse-deterrent formulation. A current U.S. sales forecast is effectively zero unless a company reintroduces the product under a new commercial strategy.

What is Zohydro ER and what market did it target?

Zohydro ER contains hydrocodone bitartrate in an extended-release capsule designed for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment when alternative treatments are inadequate. It is an oral Schedule II opioid analgesic.

Attribute Zohydro ER
Active ingredient Hydrocodone bitartrate
Dosage form Extended-release oral capsule
FDA application NDA 202880
Initial FDA approval October 2013
Original developer Zogenix Inc.
Later commercial partner Pernix Therapeutics
Therapeutic class Extended-release opioid analgesic
Controlled-substance status Schedule II
Primary market U.S. chronic pain
Abuse-deterrent formulation No
Current commercial outlook Negligible without relaunch

The product entered a market dominated by established extended-release opioids, including OxyContin, Opana ER, Exalgo and generic extended-release morphine. Zohydro ER attempted to compete on hydrocodone content and dosing flexibility rather than on abuse-deterrent technology.

The initial product did not contain acetaminophen. That distinction addressed the risk of acetaminophen-related liver toxicity associated with combination hydrocodone products, but it also left Zohydro ER exposed to criticism over the abuse potential of a high-dose hydrocodone product without abuse-deterrent properties.

How large was the Zohydro ER market opportunity?

The original opportunity was substantial on a theoretical basis but narrow in practical terms. Hydrocodone was one of the most commonly prescribed opioid ingredients in the United States, yet most prescriptions were for immediate-release hydrocodone-acetaminophen products. Zohydro ER had to convert patients from established therapies into a restricted, higher-cost, extended-release product.

The addressable market had four constraints:

  1. Extended-release opioids were reserved for patients with persistent severe pain.
  2. Payers commonly required prior authorization or step therapy.
  3. Prescribers faced growing regulatory and reputational pressure regarding long-term opioid use.
  4. Hospitals and health systems reduced opioid exposure and expanded non-opioid pain protocols.

The FDA’s approval of Zohydro ER generated public and professional opposition because the original product lacked abuse-deterrent properties. The FDA later issued guidance encouraging abuse-deterrent formulations but did not require every extended-release opioid to use such technology as a condition of approval (U.S. Food and Drug Administration, 2015).

What were Zohydro ER sales and commercial results?

Public company filings do not provide a consistent, standalone, audited long-term revenue series for Zohydro ER. The product was reported within broader Pernix commercial portfolios, and disclosures changed as the company restructured its operations.

The available commercial record supports three conclusions:

  • Zohydro ER achieved limited penetration relative to leading extended-release opioids.
  • Revenue did not develop into a durable growth platform for either Zogenix or Pernix.
  • The product’s commercial value declined as opioid restrictions and payer controls intensified.

Zogenix transferred U.S. commercial rights for Zohydro ER to Pernix as part of a broader strategic transaction. Pernix subsequently managed the product within a portfolio that included Treximet, Silenor and other specialty products. Pernix later entered bankruptcy proceedings, which weakened its ability to invest in promotion, manufacturing continuity and market access.

Historical sales assessment

Because standalone annual sales are not consistently disclosed, the most defensible historical classification is:

Period Commercial assessment
2013 FDA approval; no meaningful commercial revenue
2014 Initial launch; limited uptake
2015-2016 Commercialization under Zogenix and later Pernix
2017-2018 Mature but declining specialty opioid product
2019 onward Commercial disruption and negligible market visibility
Current outlook No material recurring revenue base

Zohydro ER should not be valued as an established branded-growth asset. Its historical revenue potential was dependent on physician promotion and payer access, both of which deteriorated.

What is the current FDA regulatory status of Zohydro ER?

Zohydro ER was approved under FDA NDA 202880. Its approval established hydrocodone bitartrate extended-release capsules as a treatment for severe, persistent pain requiring continuous opioid therapy. The product was approved with a boxed warning addressing addiction, abuse, misuse, overdose and death, consistent with the regulatory framework for extended-release and long-acting opioids.

The product’s regulatory position is weakened by the lack of abuse-deterrent labeling. FDA-approved abuse-deterrent labeling can influence formulary placement, institutional policy and prescriber perception, although it does not eliminate abuse or guarantee favorable reimbursement.

A product can remain associated with an approved NDA while having limited or discontinued commercial distribution. FDA regulatory approval therefore does not establish an active sales channel or a current revenue opportunity.

What is the Orange Book status of Zohydro ER?

Zohydro ER was listed in the FDA Orange Book as an approved prescription drug product associated with NDA 202880. Orange Book relevance depends on whether the NDA remains active, whether patent information remains listed, and whether the product is identified as discontinued for reasons other than safety or effectiveness.

The practical Orange Book implications are limited:

  • No broad generic market has displaced Zohydro ER in the way generic immediate-release hydrocodone displaced branded combination products.
  • The small commercial opportunity reduces the incentive for generic manufacturers to incur development, controlled-substance manufacturing and regulatory costs.
  • Any remaining listed patent would have limited economic value unless the product were relaunched or a generic entrant identified a commercially attractive market.

The absence of meaningful generic competition does not indicate strong market demand. It can reflect a market that is too small, too regulated or too commercially unattractive to support generic entry.

When did Zohydro ER lose exclusivity?

Zohydro ER’s commercial exclusivity did not depend only on patent expiration. FDA regulatory exclusivity, listed patents, controlled-substance manufacturing requirements and market withdrawal all affect practical exclusivity.

The product received standard new-drug approval rather than a durable biologic-style exclusivity period. Any five-year new chemical entity exclusivity would have been relevant primarily to abbreviated new drug applications during the early post-approval period. Patent protection, if applicable to the formulation or delivery system, would have extended beyond that period, but its value was constrained by declining demand.

The key distinction is:

Type of protection Commercial relevance
FDA approval Allowed lawful marketing
New chemical entity exclusivity Limited early generic filing pathway
Formulation patents Could delay specific generic challenges
Method-of-use patents Potentially narrow and difficult to enforce
Controlled-substance controls Increased manufacturing and distribution barriers
Brand equity Weak relative to established opioid brands

There is no commercially credible basis to project a major post-exclusivity price collapse because Zohydro ER had already lost substantial market momentum before exclusivity became the central issue.

What patent protection covers Zohydro ER?

Zohydro ER’s intellectual-property position centered on extended-release hydrocodone formulations, dosing characteristics and delivery technology rather than on a novel active ingredient. The active ingredient, hydrocodone, was long established and could not provide meaningful composition-of-matter exclusivity.

Potentially relevant claim categories included:

  • Extended-release hydrocodone compositions.
  • Capsule formulations containing hydrocodone bitartrate.
  • Drug-release profiles.
  • Dosing regimens for chronic pain.
  • Manufacturing methods for controlled-release opioid products.

Formulation patents can create a barrier to a generic that copies the same release mechanism, but they do not necessarily prevent a competitor from developing a different extended-release formulation. Method-of-use patents are often narrower because they must identify a specific patient population, dosing regimen or therapeutic use.

Patent strength was therefore moderate at the formulation level and weak at the molecule level. It was also commercially weakened by the small market and the absence of a compelling product differentiation strategy.

Were there Paragraph IV challenges or major patent litigation?

No major, commercially consequential Paragraph IV challenge is broadly associated with Zohydro ER in the public record comparable to the high-profile litigation involving OxyContin, Subsys or other major opioid products.

The limited generic activity likely reflects several factors:

  • Small expected market size.
  • Controlled-substance manufacturing requirements.
  • Opioid quota and distribution controls.
  • Litigation costs relative to expected sales.
  • Declining physician demand.
  • Potential reputational exposure associated with opioid commercialization.

The absence of prominent Paragraph IV litigation should not be interpreted as evidence of an especially strong patent estate. It is more consistent with a weak economic incentive to challenge.

Which companies compete with Zohydro ER?

Zohydro ER competed against multiple products rather than a single direct substitute.

Competitor Competitive position
OxyContin and generic oxycodone ER Established extended-release opioid franchise
Hysingla ER Extended-release hydrocodone with abuse-deterrent properties
Xtampza ER Extended-release oxycodone with abuse-deterrent properties
Exalgo and generic hydromorphone ER Alternative high-potency extended-release opioid
Extended-release morphine Low-cost generic alternative
Methadone Low-cost opioid with specialized prescribing requirements
Immediate-release hydrocodone products Main therapeutic substitute
Non-opioid analgesics Increasingly preferred alternatives

Hysingla ER was a particularly important competitive reference because it offered extended-release hydrocodone in an abuse-deterrent formulation. Zohydro ER lacked an equivalent product attribute.

How does Zohydro ER compare with Hysingla ER?

Factor Zohydro ER Hysingla ER
Active ingredient Hydrocodone bitartrate Hydrocodone bitartrate
Extended release Yes Yes
Abuse-deterrent labeling No Yes
Product differentiation Hydrocodone without acetaminophen Hydrocodone with abuse-deterrent technology
Prescriber perception Exposed to abuse-liability criticism Better aligned with abuse-deterrent policy
Commercial durability Low Also constrained, but strategically stronger
Generic risk Limited practical competition Greater interest if market economics improve

Zohydro ER had a potentially useful clinical distinction because it avoided acetaminophen, but its lack of abuse-deterrent properties reduced its competitive value in a market increasingly shaped by opioid stewardship.

What sales projections are realistic for Zohydro ER?

The base-case forecast is negligible revenue. Assuming no relaunch, U.S. branded net sales should be modeled at approximately zero from the current period forward.

Scenario Annual U.S. net sales Probability assessment Required conditions
No relaunch $0-$1 million Highest No active commercial investment
Limited specialty relaunch $2-$10 million Low Product availability and focused prescriber targeting
Full branded relaunch $10-$30 million Very low New commercial owner, manufacturing, payer access
Abuse-deterrent reformulation $30-$75 million Very low FDA development, capital investment and differentiated labeling
Strategic acquisition value Nominal to low Low Buyer obtains supply, NDA rights and viable manufacturing

A relaunch would face substantial costs. These would include controlled-substance manufacturing, pharmacovigilance, DEA compliance, payer contracting, field sales, medical education and legal oversight. A new abuse-deterrent formulation would require development work, analytical validation, clinical or human-abuse-potential studies where applicable, FDA review and additional manufacturing investment.

A reasonable five-year base case is:

Year Base-case net sales
Year 1 $0
Year 2 $0
Year 3 $0
Year 4 $0-$1 million
Year 5 $0-$1 million

The upside case should not be treated as a probability-weighted operating forecast. It is a relaunch scenario with a low likelihood of execution and uncertain payer acceptance.

What generic launch risks exist for Zohydro ER?

Generic entry risk is technically present but commercially limited. A generic manufacturer would need to address:

  • Bioequivalence for an extended-release opioid.
  • Controlled-substance registration and quota allocation.
  • Manufacturing controls for hydrocodone.
  • Abuse, diversion and suspicious-order monitoring.
  • State-level opioid restrictions.
  • Pharmacy and wholesaler purchasing policies.
  • Low expected volume and potentially unfavorable pricing.

A generic could enter without materially changing the market because branded Zohydro ER demand is already limited. Generic launch risk is therefore more relevant to residual supply economics than to a large branded-revenue loss.

What licensing deals affected Zohydro ER?

The principal commercial transfer involved Zogenix and Pernix Therapeutics. Pernix obtained U.S. commercial rights to Zohydro ER as part of a broader portfolio transaction. The deal shifted commercialization but did not solve the underlying product problems: weak differentiation, opioid-related regulatory pressure, limited payer enthusiasm and declining prescribing.

No licensing arrangement created a durable international franchise. Zohydro ER was principally a U.S. opportunity, and its controlled-substance classification made broad geographic expansion more difficult.

How strong is the Zohydro ER commercial and patent estate?

The combined commercial and patent estate is weak to moderate, with the following profile:

Asset dimension Assessment
Active-ingredient exclusivity Weak
Formulation protection Moderate, depending on surviving claims
Method-of-use protection Narrow
FDA approval Established but commercially inactive
Abuse-deterrent differentiation Weak
Payer position Weak
Prescriber demand Weak
Manufacturing barriers Moderate
Generic threat Low in practical terms
Relaunch value Low

Zohydro ER may retain technical intellectual-property value, but that value is disconnected from commercial value. The product would require a new owner to rebuild supply, market access and physician demand in a shrinking opioid category.

Key Takeaways

  • Zohydro ER is an extended-release hydrocodone product approved by the FDA in 2013.
  • Its original commercial opportunity was undermined by opioid restrictions, payer controls and the absence of abuse-deterrent labeling.
  • Pernix Therapeutics later commercialized the product after acquiring U.S. rights from Zogenix.
  • Public disclosures do not support a reliable standalone historical sales series.
  • Current forward sales should be modeled at approximately zero without a relaunch.
  • Patent value is primarily formulation-based; hydrocodone itself does not provide meaningful new-molecule protection.
  • Generic entry risk is technically possible but economically limited.
  • Hysingla ER and other abuse-deterrent opioids had stronger product differentiation.
  • A commercial relaunch would require new manufacturing, regulatory, payer and compliance investment.
  • The product has low standalone acquisition value unless bundled with broader opioid assets or manufacturing rights.

FAQs

Is Zohydro ER still available in the United States?

Zohydro ER has no meaningful current commercial presence. FDA approval history does not establish active distribution, pharmacy availability or recurring sales.

Did Zohydro ER have abuse-deterrent technology?

No. The original Zohydro ER formulation did not carry abuse-deterrent labeling, which weakened its competitive position against products such as Hysingla ER and Xtampza ER.

Is there a generic version of Zohydro ER?

There is no significant generic market presence comparable to generic immediate-release hydrocodone. The limited opportunity, controlled-substance requirements and weak demand reduce generic manufacturers’ incentives.

Could Zohydro ER be relaunched?

A relaunch is technically possible but commercially unattractive without a new formulation, reliable manufacturing, payer access and a clear clinical or abuse-deterrent differentiation strategy.

What would Zohydro ER be worth in an acquisition?

The standalone asset would likely have nominal to low value. Any meaningful valuation would depend on transferable FDA rights, surviving formulation patents, manufacturing capability, inventory, regulatory infrastructure and a broader portfolio transaction.

References

  1. U.S. Food and Drug Administration. (2013). Zohydro ER approval and prescribing information, NDA 202880. FDA.

  2. U.S. Food and Drug Administration. (2015). Abuse-deterrent opioids: Evaluation and labeling guidance for industry. FDA.

  3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

  4. Drug Enforcement Administration. (2024). Controlled substances schedules. U.S. Department of Justice.

  5. Pernix Therapeutics Holdings, Inc. (2015-2018). Annual reports and Securities and Exchange Commission filings. U.S. Securities and Exchange Commission.

  6. Zogenix, Inc. (2013-2015). Annual reports and Securities and Exchange Commission filings. U.S. Securities and Exchange Commission.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.